HD Study NeuroSearch

HD Study NeuroSearch lead specialist product HuntexilTM (pridopidine) was the subject of several key poster presentations at this year's World Congress on Huntington's disease (WCHD) in Vancouver. Planned for market launch in 2011, HuntexilTM is in late stage clinical development as a novel therapeutic for the treatment of Huntington's disease. The focus was to share the most recent update and present supportive data on the company's two ongoing, large clinical development studies for HuntexilTM: MermaiHD in Europe and HART in North America. Both studies are designed to investigate the potential of HuntexilTM as a symptomatic treatment of the voluntary movement ability in patients with HD. The studies are randomised, double-blinded and placebo-controlled evaluating the efficacy, safety and tolerability of different HuntexilTM dosing regimens. Results